277 related articles for article (PubMed ID: 26099669)
1. PET/Computed Tomography in the Diagnosis and Staging of Gastric Cancers.
Malibari N; Hickeson M; Lisbona R
PET Clin; 2015 Jul; 10(3):311-26. PubMed ID: 26099669
[TBL] [Abstract][Full Text] [Related]
2. Metabolic information on staging FDG-PET-CT as a prognostic tool in the evaluation of 97 patients with gastric cancer.
Coupe NA; Karikios D; Chong S; Yap J; Ng W; Merrett N; Lin M
Ann Nucl Med; 2014 Feb; 28(2):128-35. PubMed ID: 24297388
[TBL] [Abstract][Full Text] [Related]
3. Lymph node staging of gastric cancer using (18)F-FDG PET: a comparison study with CT.
Yun M; Lim JS; Noh SH; Hyung WJ; Cheong JH; Bong JK; Cho A; Lee JD
J Nucl Med; 2005 Oct; 46(10):1582-8. PubMed ID: 16204706
[TBL] [Abstract][Full Text] [Related]
4. Diagnosis and evaluation of gastric cancer by positron emission tomography.
Wu CX; Zhu ZH
World J Gastroenterol; 2014 Apr; 20(16):4574-85. PubMed ID: 24782610
[TBL] [Abstract][Full Text] [Related]
5. [18F]Fluorodeoxyglucose PET/Computed Tomography in Gastrointestinal Malignancies.
Donswijk ML; Hess S; Mulders T; Lam MG
PET Clin; 2014 Oct; 9(4):421-41, v-vi. PubMed ID: 26050945
[TBL] [Abstract][Full Text] [Related]
6. Performance of (18)F-FDG PET/CT as a postoperative surveillance imaging modality for asymptomatic advanced gastric cancer patients.
Lee DY; Lee CH; Seo MJ; Lee SH; Ryu JS; Lee JJ
Ann Nucl Med; 2014 Oct; 28(8):789-95. PubMed ID: 24965850
[TBL] [Abstract][Full Text] [Related]
7. Spectrum of gastric malignancy on 18F-FDG PET/CT: a pictorial essay.
Makis W; Ciarallo A; Hickeson M; Rush C; Derbekyan V; Novales-Diaz JA; Laufer J; Stern J; Lisbona R
Clin Imaging; 2012; 36(5):432-46. PubMed ID: 22920343
[TBL] [Abstract][Full Text] [Related]
8. A prospective evaluation of the utility of 2-deoxy-2-[(18) F]fluoro-D-glucose positron emission tomography and computed tomography in staging locally advanced gastric cancer.
Smyth E; Schöder H; Strong VE; Capanu M; Kelsen DP; Coit DG; Shah MA
Cancer; 2012 Nov; 118(22):5481-8. PubMed ID: 22549558
[TBL] [Abstract][Full Text] [Related]
9. FDG PET-CT for lymph node staging of bladder cancer: a prospective study of patients with extended pelvic lymphadenectomy.
Jeong IG; Hong S; You D; Hong JH; Ahn H; Kim CS
Ann Surg Oncol; 2015 Sep; 22(9):3150-6. PubMed ID: 25634779
[TBL] [Abstract][Full Text] [Related]
10. Impact of Fluorodeoxyglucose PET/Computed Tomography on the Management of Patients with Colorectal Cancer.
Laurens ST; Oyen WJ
PET Clin; 2015 Jul; 10(3):345-60. PubMed ID: 26099671
[TBL] [Abstract][Full Text] [Related]
11. Comparison between 18F-FDG PET/MRI and MDCT for the assessment of preoperative staging and resectability of gastric cancer.
Lee DH; Kim SH; Joo I; Hur BY; Han JK
Eur J Radiol; 2016 Jun; 85(6):1085-91. PubMed ID: 27161056
[TBL] [Abstract][Full Text] [Related]
12. Usefulness of combined PET/CT to assess regional lymph node involvement in gastric cancer.
Park K; Jang G; Baek S; Song H
Tumori; 2014; 100(2):201-6. PubMed ID: 24852866
[TBL] [Abstract][Full Text] [Related]
13. PET and PET-CT in esophageal and gastric cancer.
Wieder HA; Krause BJ; Herrmann K
Methods Mol Biol; 2011; 727():59-76. PubMed ID: 21331929
[TBL] [Abstract][Full Text] [Related]
14. FDG-PET/CT for the preoperative lymph node staging of invasive bladder cancer.
Swinnen G; Maes A; Pottel H; Vanneste A; Billiet I; Lesage K; Werbrouck P
Eur Urol; 2010 Apr; 57(4):641-7. PubMed ID: 19477579
[TBL] [Abstract][Full Text] [Related]
15. Utility of contrast-enhanced FDG-PET/CT in the clinical management of pancreatic cancer: impact on diagnosis, staging, evaluation of treatment response, and detection of recurrence.
Asagi A; Ohta K; Nasu J; Tanada M; Nadano S; Nishimura R; Teramoto N; Yamamoto K; Inoue T; Iguchi H
Pancreas; 2013 Jan; 42(1):11-9. PubMed ID: 22699206
[TBL] [Abstract][Full Text] [Related]
16. Contrast-enhanced [(18)F]fluorodeoxyglucose-positron emission tomography/computed tomography for staging and radiotherapy planning in patients with anal cancer.
Bannas P; Weber C; Adam G; Frenzel T; Derlin T; Mester J; Klutmann S
Int J Radiat Oncol Biol Phys; 2011 Oct; 81(2):445-51. PubMed ID: 20832181
[TBL] [Abstract][Full Text] [Related]
17. FDG PET/CT in the management of colorectal and anal cancers.
Agarwal A; Marcus C; Xiao J; Nene P; Kachnic LA; Subramaniam RM
AJR Am J Roentgenol; 2014 Nov; 203(5):1109-19. PubMed ID: 25341152
[TBL] [Abstract][Full Text] [Related]
18. ¹⁸F-Fluorodeoxyglucose positron emission tomography/computed tomography finds answers in cancer patients with increasing tumor markers and negative or equivocal conventional imaging modalities.
Salem SS; Shahin MA
Nucl Med Commun; 2012 Mar; 33(3):313-21. PubMed ID: 22237387
[TBL] [Abstract][Full Text] [Related]
19. Is combined 18F-fluorodeoxyglucose-positron emission tomography/computed tomography superior to positron emission tomography or computed tomography alone for diagnosis, staging and restaging of pancreatic lesions?
Casneuf V; Delrue L; Kelles A; Van Damme N; Van Huysse J; Berrevoet F; De Vos M; Duyck P; Peeters M
Acta Gastroenterol Belg; 2007; 70(4):331-8. PubMed ID: 18330088
[TBL] [Abstract][Full Text] [Related]
20. A prospective diagnostic accuracy study of 18F-fluorodeoxyglucose positron emission tomography/computed tomography, multidetector row computed tomography, and magnetic resonance imaging in primary diagnosis and staging of pancreatic cancer.
Kauhanen SP; Komar G; Seppänen MP; Dean KI; Minn HR; Kajander SA; Rinta-Kiikka I; Alanen K; Borra RJ; Puolakkainen PA; Nuutila P; Ovaska JT
Ann Surg; 2009 Dec; 250(6):957-63. PubMed ID: 19687736
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
